Investigation of anti neutrophil cytoplasmic antibody presence with indirect immunofluorescence and enzyme-linked immunosorbent assay

Year 2022, Volume: 39 Issue: 2, 313 - 315, 18.03.2022

Demet Gür Vural , Yeliz Tanrıverdi Çaycı , Kemal Bilgin , Çağrı Çoban Asuman Bırıncı

Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA) are a family of autoantibodies that react with proteins expressed mainly in cytoplasmic granules of polymorphonuclear neutrophil granulocytes (PMNs). The ANCA test is used to diagnose small vessel vasculitis and to monitor inflammatory activity. ANCA was initially detected using indirect immunofluorescence (IIF), which allowed differentiation of different patterns, such as p-ANCA (perinuclear) and c-ANCA (cytoplasmic). It is now common to detect antibodies by immunochemical assays using purified proteins, such as Enzyme-Linked Immunosorbent Assay (ELISA). In our study, we evaluated ANCA test results studied with IIF and ELISA methods and recorded patient diagnoses in the system. Serum samples of 4524 patients who were thought to have autoimmunity in their etiology were evaluated for ANCA presence. In accordance with the recommendation of the manufacturer (Euroimmun AG, Lübeck, Germany), serum IFA technique was evaluated for the presence of p-ANCA, c-ANCA. ELISA test (Alegria, Orgentec) was used to detect antibodies against MPO and PR3. The number of ANCA IIF positive patients was 525(11.6%). When we look at the distribution of ANCAs, 275(52.5%) formalin sensitive pANCA, 95 (18%) formalin resistant pANCA, 60 formalin sensitive cANCA(11.5%), 95(18%) formalin resistant cANCA. 18 (3.4%) of ANCA IIFA positives had PR3 antigen and 22 (4.1%) had significant antibody elevation against MPO antigen., ANCA IIF positive samples, according to the diagnosis of information registered in the operating system, consist of 424 (80.8%) autoimmune and inflammatory diseases according to disease groups, 36 (6.9%) malignancies, 18 (3.4%) infectious diseases, 47 (8.9%) are other diseases which are not included in these groups. ANCA is a determinant for many diseases, especially vasculitis. ANCA, which we found in a large number of different disease groups, was found to be an indicator that should be used in the diagnosis and follow-up of many autoimmune and inflammatory diseases.

Keywords

Antineutrophilcytoplasmic antibodies, immunofluorescence, proteinase 3, myeloperoxidase

References

• 1. Bosch X, Guilabert A, Font A. Antineutrophil cytoplasmic antibodies Lancet 2006; 368: 404–18.
• 2. Weiner M, Segelmark M. The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA). Autoimmunity Reviews 15 (2016) 978–982.
• 3. Savige J, Gillis D, Benson E, et al. International Consensus Statement on Testing and Reporting of AntineutrophilCytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999; 111:507–513.
• 4. Savige J, Dimech W, Fritzler M, et al. Addendum to theInternational Consensus Statement on testing and reporting ofantineutrophil cytoplasmic antibodies. Quality control guidelines,comments, and recommendations for testing in other autoimmunediseases. Am J Clin Pathol 2003; 120: 312–318.
• 5. Avery T Y, Bons J , Van Paassen Pand , Damoiseaux J. Diagnostic ANCA algorithms in daily clinical practice: evidence, experience, and effectiveness. Lupus (2016) 25, 917–924 .
• 6. Roozendaal C and Kallenberg C G M. Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD) . Clin Exp Immunol. 1999 May; 116(2): 206–213.doi: 10.1046/j.1365-2249.1999.00905.x
• 7. Özdemir M, Feyzioğlu B, Gündem N S, Baykan M, Baysal B. Otoimmün hastalıklarda antinötrofil sitoplazmik antikorların Araştırılması. Genel Tıp Derg 2012;22(1).
• 8. Schlaffke J , Zozulińska D , Wierusz-Wysocka B Polskie Archiwum Medycyny Wewnetrznej Assessment of antineutrophil-cytoplasmic autoantibodies (ANCA) in type 1 diabetic patients]. [01 Jun 2005, 113(6):552-556].
• 9. Mulder AHL, Horst G, Van Leeuwen MA, Limburg, PC, Kallenberg, CGM. Antineutrophil cytoplasmic antibodies inrheumatoid arthritis characterization and clinical correlations. Arthritis Rheum 1993;36:1054-60.
• 10. De Bandt M, Meyer O, Haim T, Kahn MF. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis patients. Br J Rheumatol. 1996;35:38-43.
• 11. Schnabel A, Csernok E, Isenberg DA, Mrowka C, Gross WL: Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance. Arthritis Rheum 1995, 38(5):633.
• 12. Weiner M, Segelmark M. The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA). Autoimmun Rev. 2016 Oct;15(10):978-82. doi: 10.1016/j.autrev.
• 13. Kılıç ZMY, Tunç B, Ayaz S, Filik S, Aktaş S. Antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies in inflammatory bowel diseases. Turk J Gastroenterol 2004;15: 238-42